We demonstrated that the FOXN3-NEAT1-SIN3A complex promotes EMT and invasion of breast cancer cells in vitro as well as dissemination and metastasis of breast cancer in vivo.
In the present study, lncRNA NEAT1 was detected to be significantly upregulated in NSCLC tissues and closely associated with advanced TNM stages, lymph node metastasis, distant metastasis, and poor prognosis.
Therefore, nuclear-enriched RBP, PTBP3, promotes HCC cell malignant growth and metastasis by regulating the balance of splicing variants (NEAT1_1, NEAT1_2 and miR-612) in HCC.
These results provided the first evidence that the expression of NEAT1 in colorectal cancer may play an oncogenic role in colorectal cancer differentiation, invasion and metastasis.
LncRNA NEAT1 was overexpressed in gastric cancer tissues and cell lines and corrected with clinical stage, histological type, lymph node metastasis, and distant metastasis.
NEAT1 and CDK6 could promote cell proliferation and metastasis of glioma cells and impeded cell apoptosis, whereas miR-139-5p exerted suppressive effects on the biological functions of glioma cells.
The results also indicated that NEAT1 expression was highly associated with tumor size (>3 cm vs. ≤3 cm; odds ratio [OR]=2.51, 95% CI: 1.27-4.99; p=0.009), TNM stage (III+IV vs. I+II; OR=4.17, 95% CI: 2.42-7.18; p=0.00001), and distant metastasis (OR=2.73, 95% CI: 1.28-5.79; p=0.01).
The high level of NEAT1 expression can predict the metastasis of lymph node (OR = 3.36, 95% CI = 1.66-6.77, <i>p</i> = .000) and it is a molecular marker of positive lymph node for treatment.
Critical roles of NEAT1 in regulation of apoptosis, cell growth and proliferation, invasion and metastasis in several tissues indicate that this lncRNA might be a therapeutic target in various cancers.
NEAT1 level was significantly higher in LSCC than in corresponding adjacent non-neoplastic tissues, and patients with neck nodal metastasis or advanced clinical stage had higher NEAT1 expression.